Genomenon

Executive Summary

Genomenon is a US-based genomic intelligence company that transforms the vast landscape of published genomic literature into actionable evidence for clinical diagnostics and precision medicine. By leveraging AI-powered platforms and expertly curated databases, the company enables rapid identification of gene and variant-level insights aligned with professional guidelines such as ACMG/AMP. This approach accelerates diagnosis for rare diseases and cancer while supporting pharmaceutical companies in drug development. Founded in 2014 and headquartered in Ann Arbor, Genomenon addresses the critical bottleneck of manual literature curation, offering scalable solutions for evidence-based genomics. The company's technology integrates natural language processing and machine learning to extract and contextualize genomic data from millions of scientific articles. This positions Genomenon as a key enabler in the precision medicine ecosystem, where accurate variant interpretation is essential for clinical decision-making and therapeutic targeting. As the demand for genomic data interpretation grows, Genomenon's platforms are poised to play a vital role in reducing diagnosis time and enhancing the efficiency of drug discovery pipelines. With a focus on rare diseases and oncology, the company is well-aligned with market trends toward personalized healthcare and AI-driven diagnostics.

Upcoming Catalysts (preview)

• Q2 2026Major pharmaceutical partnership or licensing deal60% success
• Q3 2026Expansion of curated database to cover additional therapeutic areas70% success
• Q4 2026Integration with leading EHR or LIS platforms50% success